Sign up to The Irish Times Archive (1859 - 2008)My Account »
Sat 10 Oct 2009Elan shares slump over Tysabri drug review
SHARES IN Elan slumped yesterday after the European Medicinces Agency (EMEA) announced a review of the risks and benefits of its key multiple sclerosis drug Tysabri in the wake of 23 cases of a rare and potentially fatal brain disease since it came to market.
The stock slid as much as 23 per cent in New York trade before rallying slightly to close 16.5 per cent weaker. In Dublin, the shares were 20.5 per cent weaker.
Choose a Subscription type - required
